EXTON, Pa., March 12, 2020 (GLOBE NEWSWIRE) -Idera Pharmaceuticals, Inc., Inc. (“Idera”) (NASDAQ: IDRA) reported on March 11, 2020 its financial and operational results for the fourth quarter and year ended December 31, 2019. “In 2019, we made great progress with...
SAN DIEGO–(BUSINESS WIRE)– Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced an interim clinical data update for cirmtuzumab, a ROR1-targeted...
Management to host webcast and conference call to review data and program strategy at 8 a.m. ET on March 18, 2020 HENDERSON, Nev.–(BUSINESS WIRE)–Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology...
PROOF 302 Trial Enrolling Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations Ohio State University-Led Trial to Study Infigratinib for Treatment of Patients with Advanced or Metastatic Solid Tumors with FGFR Genetic Alterations SAN...
The Christie NHS Foundation Trust and Innovative Trials, a clinical trial patient recruitment company, has announced a pioneering partnership to tackle the issue of patient diversity within clinical trials and help speed up research so that effective treatments come...
Netherlands Cancer Institute Intends to Sponsor and Conduct Phase 1/1b SHERPA Trial in Patients with Tumors Harboring RAS Mutations REDWOOD CITY, Calif., March 09, 2020 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (RVMD), a clinical-stage oncology company...
Email
Text